Diabetes Care, Vol 23, Issue 1 40-44, Copyright © 2000 by American Diabetes Association

ARTICLES

Similar 9-year mortality risks and reproducibility for the World Health Organization and American Diabetes Association glucose tolerance categories: the Hoorn Study

F de Vegt, JM Dekker, CD Stehouwer, G Nijpels, LM Bouter and RJ Heine
Institute for Research in Extramural Medicine, Vrije Universiteit, Amsterdam, The Netherlands.

OBJECTIVE: To compare the risks of all-cause and cardiovascular disease (CVD) mortality in the American Diabetes Association (ADA) and World Health Organization (WHO) glucose tolerance categories after 9 years of follow-up in the Hoorn Study and to study the test-retest reproducibility of those categories. RESEARCH DESIGN AND METHODS: In this population-based cohort study of 2,468 elderly men and women, subjects were classified according to both the WHO and the ADA criteria. Causes of death were extracted from the medical records. Age- and sex-adjusted relative risks were estimated by Cox's proportional hazards model. Reproducibility of the diagnostic criteria was assessed in a sample of 1,109 subjects with duplicate oral glucose tolerance tests. RESULTS: Subjects with known diabetes had a four to five times higher risk of all-cause and CVD mortality compared with normal subjects (P<0.05). The relative risks of all-cause mortality were 1.67 (95% CI 1.09-2.57) and 1.56 (1.00-2.43) for newly diagnosed diabetic subjects according to the WHO and ADA criteria, respectively. The WHO and ADA criteria had similar levels of reproducibility The overall K was 0.59 (0.54-0.64) for WHO criteria and 0.61 (0.56-0.66) for ADA criteria. For the category of newly diagnosed diabetes according to WHO or ADA, the percentages of agreement for the second test compared with the first test were 77% (85/110) and 74% (74/100), respectively. CONCLUSIONS: Both sets of diagnostic criteria identify criteria-specific diabetic subjects with an increased mortality risk compared with normal subjects, and the reproducibility of both criteria is similar.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. C. Ferrer-Garcia, E. Sanchez-Ballester, R. Albalat-Galera, M. Berzosa-Sanchez, and A. Herrera-Ballester Efficacy of Atorvastatin for Achieving Cholesterol Targets After LDL-Cholesterol Based Dose Selection in Patients With Type 2 Diabetes Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2008; 13(3): 183 - 188. [Abstract] [PDF]

				P. G. Scheffer, T. Teerlink, J. M. Dekker, G. Bos, G. Nijpels, M. Diamant, P. J. Kostense, C. D. A. Stehouwer, and R. J. Heine Increased Plasma Apolipoprotein C-III Concentration Independently Predicts Cardiovascular Mortality: The Hoorn Study Clin. Chem., August 1, 2008; 54(8): 1325 - 1330. [Abstract] [Full Text] [PDF]

				P. Mackin, D. Bishop, H. Watkinson, and I. Ferrier A prospective study of glycaemic status in anti-psychotic-treated patients J Psychopharmacol, July 1, 2008; 22(5): 563 - 566. [Abstract] [PDF]

				K. Marsh and J. Brand-Miller State of the Art Reviews: Glycemic Index, Obesity, and Chronic Disease American Journal of Lifestyle Medicine, April 1, 2008; 2(2): 142 - 150. [Abstract] [PDF]

				J. M. Dekker and B. Balkau Counterpoint: Impaired Fasting Glucose: The Case Against the New American Diabetes Association Guidelines Diabetes Care, May 1, 2006; 29(5): 1173 - 1175. [Full Text] [PDF]

				J. de Jager, J. M. Dekker, A. Kooy, P. J. Kostense, G. Nijpels, R. J. Heine, L. M. Bouter, and C. D.A. Stehouwer Endothelial Dysfunction and Low-Grade Inflammation Explain Much of the Excess Cardiovascular Mortality in Individuals With Type 2 Diabetes: The Hoorn Study Arterioscler. Thromb. Vasc. Biol., May 1, 2006; 26(5): 1086 - 1093. [Abstract] [Full Text] [PDF]

				Expert Committee on the Diagnosis and Classificati Follow-up Report on the Diagnosis of Diabetes Mellitus Clin. Diabetes, April 1, 2004; 22(2): 71 - 79. [Full Text] [PDF]

				Follow-up Report on the Diagnosis of Diabetes Mellitus Diabetes Spectr, January 1, 2004; 17(1): 51 - 59. [Full Text] [PDF]

				The Expert Committee on the Diagnosis and Classifi Follow-up Report on the Diagnosis of Diabetes Mellitus Diabetes Care, November 1, 2003; 26(11): 3160 - 3167. [Full Text] [PDF]

				J.-L. Chiasson, R. G. Josse, R. Gomis, M. Hanefeld, A. Karasik, and M. Laakso Acarbose Treatment and the Risk of Cardiovascular Disease and Hypertension in Patients With Impaired Glucose Tolerance: The STOP-NIDDM Trial JAMA, July 23, 2003; 290(4): 486 - 494. [Abstract] [Full Text] [PDF]

				B. L. Rodriguez, R. D. Abbott, W. Fujimoto, B. Waitzfelder, R. Chen, K. Masaki, I. Schatz, H. Petrovitch, W. Ross, K. Yano, et al. The American Diabetes Association and World Health Organization Classifications for Diabetes: Their impact on diabetes prevalence and total and cardiovascular disease mortality in elderly Japanese-American men Diabetes Care, June 1, 2002; 25(6): 951 - 955. [Abstract] [Full Text] [PDF]

				The Diabetes Atorvastatin Lipid Intervention DALI The Effect of Aggressive Versus Standard Lipid Lowering by Atorvastatin on Diabetic Dyslipidemia: The DALI Study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia Diabetes Care, August 1, 2001; 24(8): 1335 - 1341. [Abstract] [Full Text] [PDF]

				F. de Vegt, J. M. Dekker, A. Jager, E. Hienkens, P. J. Kostense, C. D. A. Stehouwer, G. Nijpels, L. M. Bouter, and R. J. Heine Relation of Impaired Fasting and Postload Glucose With Incident Type 2 Diabetes in a Dutch Population: The Hoorn Study JAMA, April 25, 2001; 285(16): 2109 - 2113. [Abstract] [Full Text] [PDF]